Evidence map›Paper›PMID 36405054›Full record

ArticleChinese herbal medicines2022

Taxifolin attenuates inflammation via suppressing MAPK signal pathway

Xingyan Zhang, Xiaoyan Lian, Huling Li, Wenjing Zhao, Xin Li, Fujun Zhou, Yutong Zhou, Tao Cui, Yuli Wang, Changxiao Liu

Open access · goldAbstract read
In one paragraph

Article in Chinese herbal medicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Xingyan ZhangKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Xiaoyan LianCenter for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Huling LiKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Wenjing ZhaoKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Xin LiKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Fujun ZhouKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Yutong ZhouKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Tao CuiKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Yuli WangKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Changxiao LiuKey Laboratory of Quality-marker of Traditional Chinese Medicines, Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin 300462, China.
Tianjin Institute of Pharmaceutical Research (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNNational Medical Products Administration · CNTianjin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Taxifolin is a natural flavonoid compound that can be isolated from onions, grapes, oranges and grapefruit. It also acts as a medicine food homology with extraordinary antioxidant and anti-inflammatory activity. This study aims to explain the protective effects and potential mechanisms of taxifolin against inflammatory reaction. Methods: Levels of interleukin (IL)-6, IL-1β and intracellular reactive oxygen species (ROS) were assessed in different time after the treatment of taxifolin in RAW264.7 cells induced by lipopolysaccharide (LPS). Subsequently, the mRNA and protein levels of inducible nitric oxide synthase (iNOS), vascular endothelial growth factor (VEGF), cyclooxygenase (COX)-2, tumor necrosis factor (TNF)-α and the phosphorylation expression levels of the MAPK signal pathway were also evaluated. A silico analysis was used to explain the binding situation for the investigation of taxifolin and MAPK signal pathway. And then MAPK inhibitors were used to reveal the expression level of iNOS, VEGF, COX-2 and TNF-α in RAW264.7 cells. Results: It was demonstrated that cell inflammatory damage induced by LPS was significantly alleviated after the treatment of taxifolin. Then, the mRNA and protein levels of iNOS, VEGF, COX-2 and TNF-α were reduced and the phosphorylation expression levels of the MAPK signal pathway were down-regulated remarkably as well. In silico analysis, taxifolin could form a relatively stable combination with MAPK signal pathway. MAPK inhibitors showed increasing or decreasing effect in the mRNA levels of iNOS, VEGF, COX-2 and TNF-α, which suggesting that taxifolin down-regulated iNOS, VEGF, COX-2 and TNF-α expressions were not entirely through the MAPK pathway. Conclusion: This finding demonstrated that taxifolin improved the inflammatory responses that partly involved in the phosphorylation expression level of MAPK signal pathway in RAW264.7 cells exposed to acute stress.

Indexed as

MAPK signal pathwaymolecular dockingpro-inflammatory cytokinestaxifolin

Identifiers

PMID36405054
PMCPMC9669345
OpenAlexW4294051698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.